《海拔咨询》：福音！国内首例使用“塞利尼索”患者获准“带药离园”

2020年9月初被美国FDA批准上市的普拉替尼，是一款针对非小细胞肺癌RET基因融合突变的靶向新药。该药已于9月底同步特许进入海南博鳌乐城国际医疗旅游先行区的博鳌超级医院。 Plalsetinib, approved by FDA in early September 2020, is a new targeted drug treating RET gene fusion mutations in NSCLC.Through the end of September, the drug was licensed into the Boao Super Hospital in Hainan BoaoLecheng International Medical Tourism pilot zone.